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Abstract
Tumor invasion and metastasis involves complex remodeling of gene expression programs governing epithelial
homeostasis. Mutational activation of the RAS-ERK is a frequent occurrence in many cancers and has been shown to
drive overexpression of the AP-1 family transcription factor FRA1, a potent regulator of migration and invasion in a variety of
tumor cell types. However, the nature of FRA1 transcriptional targets and the molecular pathways through which they
promote tumor progression remain poorly understood. We found that FRA1 was strongly expressed in tumor cells at the
invasive front of human colorectal cancers (CRCs), and that its depletion suppressed mesenchymal-like features in CRC cells
in vitro. Genome-wide analysis of FRA1 chromatin occupancy and transcriptional regulation identified epithelial-
mesenchymal transition (EMT)-related genes as a major class of direct FRA1 targets in CRC cells. Expression of the pro-
mesenchymal subset of these genes predicted adverse outcomes in CRC patients, and involved FRA-1-dependent
regulation and cooperation with TGFb signaling pathway. Our findings reveal an unexpectedly widespread and direct role
for FRA1 in control of epithelial-mesenchymal plasticity in CRC cells, and suggest that FRA1 plays an important role in
mediating cross talk between oncogenic RAS-ERK and TGFb signaling networks during tumor progression.
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Introduction
Local invasion and metastasis of colorectal and some other
carcinoma types is thought to involve transient remodeling of the
epithelial tumor cell phenotype to an invasive mesenchymal-like
state, characterized by defects in tight and adherens junction
formation, increase in intermediate filament proteins (e.g.
vimentin), and elevated expression of proteases mediating degra-
dation of the extracellular matrix. Such epithelial-mesenchymal
transitions (EMT) and mesenchymal-epithelial transitions (MET)
involve extensive and highly coordinated changes in gene
expression, regulated by complex signalling and transcription
factor networks that engage master EMT transcription factors
belonging to the basic helix-loop-helix (bHLH), Snail, Twist and
ZEB families [1–3].
Colorectal cancer (CRC) is a genetically heterogeneous disease
whose metastatic spread to the liver, lung, peritoneal cavity and
bones poses major clinical problems [4]. More than 50% of CRCs
harbor oncogenic mutations in the KRAS or BRAF genes, which
drive persistent activation of the ERK MAPK pathway. These
mutations generally arise at a relatively early stage during
adenoma-carcinoma progression, following functional loss of the
tumor suppressor APC, and their high incidence of concordance
in primary and metastatic cancers suggests that they contribute to
both tumor initiation and progression [5–8]. At later stages, some
tumors acquire mutations (TGFBR2, SMAD2, SMAD3 or SMAD4)
that disrupt signaling via the TGFb pathway, which provides
growth inhibitory signals in the normal intestinal epithelium.
In CRC, EMT-like events are strongly associated with budding,
a pathological phenomenon observed in 20–40% of cases, in
which tumor cells detach from the invasive front and invade into
the surrounding basement membrane [9,10]. The interplay
between EMT and MET has also been suggested to underlie the
observation that basement membrane expression is often lost at
the invasive front of CRCs, but regained in metastases [11]. More
recently, several studies have identified EMT-related gene
expression signatures as a common occurrence in primary CRCs,
which are strongly associated with poor prognosis and resistance to
targeted therapies [12–15].
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One of the major pathways involved in induction and
maintenance of EMT events during development and tumorigen-
esis is the TGFb pathway. Although activation of the pathway is
growth inhibitory in normal epithelial cells, oncogenic RAS-ERK
signaling has been reported to induce a paradoxical switch in its
role from tumour suppressor to pro-metastatic factor, in part
through activation of EMT-related programs [2,16–19]. The
mechanisms underlying pro-malignant cross talk between the RAS
and TGFb pathways during CRC progression are not well
understood. Perturbation of the TGFb pathway is a frequent event
in CRC. Complete inactivation of TGFb signaling through
mutation of the type II TGFb receptor (TGFBR2) locus is a
common occurrence in the 15% of CRCs displaying DNA
microsatellite instability (MSI), which ironically are associated with
favorable prognostic outcomes [20]. The remaining 85% of
microsatellite stable (MSS) cancers display chromosomal instability
(CIN), and often (,50% of cases) harbor mutations in the SMAD4
gene, and less frequently the SMAD2 and SMAD3 genes [21].
Recent studies have shown that the TGFBR2 genotype is the major
factor determining a lack of EMT-like responses to TGFb1 in
MSI-positive tumors, whereas CRC cells with SMAD4 mutations
retain the ability to undergo EMT upon TGFb1 treatment
through coupling with the ERK pathway [22]. The nature of
ERK pathway effectors required for these responses are presently
unclear.
The Activator Protein-1 complex is a key regulator of
transcriptional responses induced by various cancer-associated
signalling pathways. It consists of homo- or hetero-dimers of Fos,
Jun, ATF and MAF family members, whose activities are strongly
influenced by oncogenic signaling events. Activating mutations in
RAS pathway components have been shown to induce overex-
pression of the Fos family member FRA1, a highly unstable
protein that is expressed at low levels in normal cells [23,24].
Transcriptional induction and post-translational stabilization of
FRA1 by oncogenic RAS-ERK signaling increases the relative
abundance of FRA1 containing AP-1 dimers, which has been
causally linked enhanced migration and invasion of CRC and
multiple other carcinoma cell types, including breast, lung,
bladder, head and neck, thyroid and brain [6,23–34]. In addition
to the RAS-ERK pathway, FRA1 expression is induced by the
Wnt/b-catenin pathway in CRC cells [40,41], suggesting that it
may play a role in integrating signaling through these pathways
during CRC progression.
In the present study, we applied a genome-wide approach to
better understand the nature of transcriptional programs under-
lying the pro-malignant actions of FRA1 in CRC. We found that
FRA1 binds and regulates expression of a clinically relevant cohort
of genes associated with EMT in invasive CRC cells, with stable
FRA1 knockdown invoking a MET-like phenotypic switch. FRA1
was strongly enriched in budding tumor cells at the invasive front
of human CRCs, and expression of its pro-mesenchymal targets
identified a subset of primary cancers with poor prognosis.
Mechanistically, we found that activation of mesenchymal genes
involved FRA1-dependent regulation and cooperation with TGFb
signaling networks. Collectively, our findings suggest that FRA1
plays a widespread and direct role in transcriptional control of
epithelial-mesenchymal programming during CRC progression.
Results
FRA1 is enriched in tumor cells at the invasive front of
human CRCs
Although it was previously reported that FRA1 is more highly
expressed in CRCs than the normal colorectal epithelium [35], its
relationship with tumor pathology has not been established. Using
immunohistochemistry, we detected FRA1 immunoreactivity in
20 out of 25 primary tumor specimens. In contrast to its weak
expression in the center of tumors, cells at the invasive front
exhibited strong FRA1 staining (Figure 1A–1C), including
cytokeratin AE1/AE3 positive clusters of cells [36] that had
detached from the tumor bulk (Figure 1D). This latter feature is
indicative of tumor budding, a phenomenon associated with the
acquisition of mesenchymal-like features by CRC cells, and is an
independent predictor of lymph node metastasis, vascular and
lymphatic invasion, distant metastasis, local recurrence and poor
disease-free survival [9].
FRA1 regulates mesenchymal-like features in CRC cells
Previous investigations on the pro-invasive actions of FRA1 in
CRC have used the BE cell line model, which comprises highly
invasive mesenchymal-like cells that harbor KRAS/BRAF muta-
tions driving high endogenous FRA1 expression [33,37]. Consis-
tent with its role as a major contributor to AP-1 activity in these
cells, stable knockdown of FRA1 using 2 distinct shRNAs
constructs reduced both basal and c-Jun stimulated AP-1 reporter
gene activation (Figure 2A and 2B). Phenotypically, FRA1
depletion invoked a striking mesenchymal to epithelial-like
morphological switch, with cells acquiring a flattened appearance,
regaining expression of the epithelial differentiation marker E-
cadherin, and forming tight junctions staining positively for ZO-1
(Figure 2A and 2C). In addition, FRA1-depleted cells almost
completely lost their capacity to migrate and invade in vitro, but
their proliferation rates remained unchanged (Figure 2D–2F).
Together, these findings suggest a requirement for FRA1 to
maintain CRC cells in a mesenchymal-like state.
Figure 1. Enrichment of FRA1 in tumor cells at the invasive
front of human CRCs. (A) Low power image of a representative
colorectal carcinoma stained with an antibody detecting FRA1. The
asterisk indicates the lumen, while the arrowheads indicate the deep
invasive front. Scale bar represents 1 mm. (B and C) High power images
of the tumor centre (TC) and invasive front (IF) shown in (A).
Arrowheads indicate tumor buds. Scale bar represents 10 mM. (D)
Relationship between the intensity of nuclear FRA1 expression and the
tumor budding marker, cytokeratin AE1/AE3 in 25 CRC cases.
doi:10.1371/journal.pone.0088950.g001
FRA1 Regulation of EMT
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EMT-related genes are a major class of direct FRA1
targets in CRC cells
To identify direct transcriptional targets and molecular path-
ways through which FRA1 controls mesenchymal-like features in
tumor cells, we performed genome-wide ChIP-Seq and transcrip-
tome analysis to search for genes at which FRA1 binding was
enriched, and whose expression was regulated by FRA1 in BE
cells. Despite several attempts to optimize the ChIP assay using
antibodies targeting endogenous FRA1, we were unable to recover
sufficient chromatin to perform subsequent high-throughput
sequencing. We therefore generated BE cell lines moderately
(,5-fold higher than endogenous FRA1) overexpressing a FLAG-
FRA1 protein, which was localized in the nucleus (Figure 3A,B). In
contrast to a DNA binding defective variant, wild-type FLAG-
FRA1 demonstrated strong enrichment at the promoter of VIM, a
previously identified direct FRA1 target (Figure 3C) [38].
Using microarrays, we found that FRA1 knockdown in BE cells
significantly up-regulated expression of 1392 genes while reducing
expression of 832 genes by at least 2-fold (Figure 3D). ChIP-Seq
analysis revealed that 72% percent of the FRA1-regulated genes
contained loci significantly enriched for FRA1 binding (.5-fold)
within 5 kb of their transcription start site (TSS). To identify major
functional classes of FRA1 target genes, we intersected the
microarray and ChIP-Seq data and interrogated overlapping
genes for enrichment of gene ontology terms (using GeneGo). Of
the top 6 groups identified using this approach, 3 were significantly
enriched for genes associated with EMT-related processes, while a
further 3 groups featured adhesion-related genes (Figure 3E).
These findings indicated that EMT and adhesion are two major
processes under direct FRA1 transcriptional control in CRC cells.
Based on the phenotypic changes resulting from FRA1
knockdown in BE cells, and the association between tumour
budding and EMT in CRC [9], we chose to focus on the
involvement of FRA1 in regulating EMT events in CRC.
Collectively the EMT-related genes bound and regulated by
FRA1 (herein termed FRA1EMT genes) encoded a diverse array of
proteins involved cell adhesion, signal transduction, transcription,
cytoskeletal and extracellular matrix remodeling, as well as
components of TGFb signaling networks (Figure 4A and Table
S1 in File S1). These genes broadly comprised a pro-mesenchymal
subset whose expression was promoted by FRA1 and an epithelial
subset that was repressed by FRA1. Many of the genes contained
multiple loci occupied by FRA1, which were primarily located
within intronic regions of the gene body and in distal upstream
sites (Figure 4B and Table S2 in File S1). Motif analysis revealed
that 58% of the genes contained at least one FRA1 binding site
Figure 2. FRA1 knockdown suppresses mesenchymal-like features in CRC cells. (A) Immunoblot analysis of FRA1 and E-cadherin levels in
BE cells stably transduced with a non-silencing control (shNS) or FRA1-targeting shRNAs (shFRA1-A and -B). (B) Effect of FRA1 knockdown on basal
and c-Jun-induced AP-1 reporter gene activity in BE cells. (C) Phase-contrast images (top row) and immunofluorescence staining for DAPI with ZO-1
(middle row) or vimentin (bottom row) on the cells from (A). Scale bar represents 10 mM. (D–F) Analysis of in vitro migration, invasion and
proliferation in cells from (A). Error bars represent S.E.M. for 3 independent experiments.
doi:10.1371/journal.pone.0088950.g002
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significantly enriched for a consensus AP-1 binding sequence
(p,0.0001, Table S3 in File S1). We also noted significant
enrichment (p,0.001) for putative MEF-2 motifs in the EMT-
related targets identified in the ChIP-Seq analysis. Finally, we
performed ChIP and qRT-PCR analysis to confirm enrichment of
FRA1 at several loci identified by ChIP-Seq (Figure 4C) and
FRA1-dependent regulation of selected targets in BE cells
(Figure 4D).
Expression of pro-mesenchymal FRA1 targets predicts
poor clinical outcomes
To assess the potential clinical relevance of the EMT-related
FRA1 targets, we examined the relationship between their
expression and CRC prognosis by interrogating existing micro-
array data from 185 stage B and C cases [12]. Unsupervised
clustering of the data revealed that tumors could be classified into
epithelial- and mesenchymal-like subgroups displaying gene
expression differences highly concordant with the FRA1EMT
signature (Figure 5B and Table S4 in File S1), with 77% of genes
(137 probesets) showing directional changes consistent with those
identified upon FRA1 knockdown in BE cells.
We also found that high levels of FRA1 gene (FOSL1) expression
independently predicted poor recurrence-free survival and was
associated with a higher T-stage, an index of advanced tumor
invasion (Figure 5A and Table S5 in File S1). Although FOSL1
expression was detected in both epithelial- and mesenchymal-like
tumors, its expression was significantly higher (p,0.05) in the
latter group. Expression of pro-mesenchymal FRA1 targets was
enriched in 48.6% (90/185) of primary tumours, which had an
earlier diagnosis age (median 64 vs 70 years, p = 0.005) and higher
lymph node stage (N2 76% vs 24%, p= 0.0098) compared to
epithelial-type tumors (Table S6 in File S1).
Integrating data on FOSL1 expression and the FRA1EMT
signature significantly improved prediction of recurrence risk,
broadly separating patients into 3 outcome-based groups
(Figure 5C and Table S7 in File S1): (i) A good prognosis group
consisting of FOSL1low epithelial-type cancers, (ii) an intermediate
prognosis group comprising FOSL1low mesenchymal-type cancers
and FOSL1high epithelial-type cancers, and (iii) a poor prognosis
group of FOSL1high mesenchymal-type cancers. These findings
suggest that the combination of elevated FOSL1 and pro-
mesenchymal FRA1 target gene expression in primary tumors
provides a robust predictor of adverse outcomes in CRC patients.
Cross talk between FRA1 and TGFb signalling controls
mesenchymal gene expression
Given their association with adverse clinical outcomes (Figure 5),
we next sought to gain a deeper mechanistic insight into FRA1-
dependent control of mesenchymal expression programs in CRC
cells. In particular, we wondered if in addition to directly binding
Figure 3. Genome-wide analysis of direct FRA1 transcriptional targets in CRC cells. (A) Immunoblot analysis of FRA1 expression in BE cells
stably transduced with a FLAG-FRA1 expression construct of vector (pBP) control. (B) Immunofluorescence analysis of FLAG-FRA1 localization in cells
from (A). (C) ChIP analysis comparing binding of wild-type and DNA binding defective (DBD) FLAG-FRA1 proteins to the VIM promoter in BE cells. (D)
Intersection of data from microarray (FRA1 shRNA) and ChIP-Seq (FLAG-FRA1) analysis in BE cells. The ChIP-Seq results represents genes at which
FRA1 binding was enriched .5-fold relative to input control within 5 kb of the transcription start site (TSS). Only annotated genes undergoing at
least a 2-fold change in expression upon FRA1 silencing (p,0.05) were considered, and genes associated with multiple FLAG-FRA1 peaks were only
counted once. (E) Ontological analysis of genes identified after intersection of the microarray and ChIP-Seq datasets. Genes were clustered into major
biological pathways using GeneGo.
doi:10.1371/journal.pone.0088950.g003
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and regulating their transcription, FRA1 could promote expres-
sion of pro-mesenchymal genes by modulating the activities of
EMT-associated signaling pathways whose components we had
identified as direct FRA1 targets. The most highly represented of
these were genes acting in TGFb signaling networks, including
those encoding activating (TGFB2) and inhibitory ligands (BMP4,
Figure 4. Characterization of EMT-related FRA1 transcriptional targets. (A) Heat map showing different functional groups of EMT-related
genes bound and regulated by FRA1 (FRA1EMT genes). Data from RNA-Seq analysis of two clones of BE shFRA1-A cells (n = 4 for each cell line) was
normalised relative to shControl cells. Regions shown in red represent genes associated with an epithelial state that were upregulated upon FRA1
silencing (log fold-change,21, p,0.05), while green regions represent mesenchymal-type genes repressed by FRA1 silencing (log fold-change.1,
p,0.05). (B) Distribution of genomic FLAG-FRA1 binding sites identified by ChIP-Seq relative to a corresponding gene. The number of reads identified
for each region is expressed as a percentage. (C) ChIP-qPCR analysis of FLAG-FRA1 binding to genomic regions in selected FRA1EMT genes. Data
represent relative enrichment compared to parental BE cells. A region of the miRNA-21 gene not bound by FLAG-FRA1 was used as negative control
(CTRL). (D) qRT-PCR analysis of selected FRA1EMT genes in BE cells stably transduced with one of two independent shRNAs targeting FRA1. Data are
represented relative to expression levels in cells shNS cells. Student’s t-test was used for all comparisons (*p,0.05, **p,0.01, ***p,0.001). Error bars
represent S.E.M. for 3 independent experiments. (E) FRA1 protein levels and (F) expression of epithelial and mesenchymal marker genes in a panel of
CRC cell lines.
doi:10.1371/journal.pone.0088950.g004
Figure 5. Clinical significance of FRA1 and FRA1EMT genes in CRC. (A) Kaplan-Meier plots of recurrence-free survival in stage B and C CRC
patients according to expression of the FRA1 gene (FOSL1). (B) Unsupervised clustering of stage B and stage C CRCs based on FRA1EMT genes
encompassing concordant probesets exhibiting significant expression differences between the two main groups. Clustering divides cancers into
groups with mesenchymal and epithelial profiles. Samples are arranged along the X-axis and genes along the Y-axis. Genes are grouped into those
downregulated (blue) or upregulated (orange) upon FRA1 knockdown in BE cells relative to the mean- and sample-centered scaled expression. (C)
Kaplan-Meier plots of recurrence-free survival in stage B and C CRC patients based on expression of both FOSL1 (low vs high) and mesenchymal (Mes,
dark green) or epithelial (Epi, light green) subsets of FRA1EMT genes. The log-rank test was used for comparisons.
doi:10.1371/journal.pone.0088950.g005
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BMP7), whose expression was promoted or repressed by FRA1,
respectively (Figure 4A, 4C and 4E). Being the only activating
ligand identified as a FRA1 target, we chose to investigate the
potential contribution of TGFb2 signaling in regulating expression
of a selection of FRA1EMT targets. Transient knockdown of
TGFB2 in parental BE cells significantly reduced expression of
several pro-mesenchymal (AXL, VIM) but not epithelial (CDH1,
CLDN7) FRA1 target genes (Figure 6A). Similar effects were also
observed upon transient knockdown of another FRA1 bound
target acting in the pathway, encoding the transcription factor
SMAD3 (Figure 6B). To directly examine the possibility that a
FRA1-dependent autocrine TGFb2 loop was operating in these
cells, they were treated with the type 1 TGFb receptor inhibitor
SB43152 to block transduction of TGFb2 signals. Consistent with
the effects of TGFB2 knockdown, we found that expression of
several pro-mesenchymal FRA1 targets (AXL, VIM, TGFBI) was
significantly reduced after 3 days of SB43152 treatment.
To further investigate the extent of cross talk between FRA1
and the TGFb pathway, we assessed the expression of several
mesenchymal and epithelial FRA1 targets in another KRAS
mutant TGFb-responsive CRC cell line, SW837. Despite FRA1
levels being elevated in these cells (Figure 7A), their expression of
the pro-mesenchymal genes VIM and AXL was low when
compared to BE cells, while the epithelial genes CDH1 and
CLDN7 were highly expressed (Figure 7B). Treatment with the
ligand TGFb1 robustly induced expression of VIM, a response that
was significantly impaired upon prior FRA1 knockdown
(Figure 7C). By contrast, expression of the epithelial FRA1 targets
CDH1 and CLDN7 was unaffected under the same conditions.
These results suggest that FRA1 expression modulates the extent
to which TGFb signaling can induce pro-mesenchymal transcrip-
tional responses in CRC cells.
Discussion
The local invasion and metastatic spread of cancers involves
specific, highly coordinated and dynamic remodeling of tumor cell
gene expression through bidirectional cross talk between signaling
and transcriptional networks. Much remains to be understood
about how these networks are regulated by tumor-associated
genetic and epigenetic lesions, and the mechanisms through which
they are coordinated to induce specific changes in gene expression
during invasion.
The transcription factor AP-1 has long been implicated as a
central regulator of tumor cell invasion [39]. FRA1 is one of the
most frequently overexpressed AP-1 proteins in solid cancers, and
its ability to promote migratory and invasive traits in a variety of
different tumor cell types [26–32] suggests that its actions involve
engagement of common targets and pathways. The identity of
these pathways is presently unclear, while only a handful of its
direct transcriptional targets in carcinoma cells identified to date.
Through analysis of its genome-wide chromatin occupancy and
target gene regulation, the present study identifies genes and
pathways involved in cell adhesion and EMT as major classes of
direct FRA1 targets associated with CRC progression.
Figure 6. A FRA1-dependent autocrine TGFb2 loop promotes mesenchymal gene expression in BE CRC cells. (A and B) Expression of
selected mesenchymal (TGFBI, AXL) and epithelial (CDH1, CLDN7) FRA1EMT genes upon transient knockdown of the TGFb pathway FRA1 targets TGFB2
and SMAD3 using siRNA pools in BE cells. Data are represented relative to levels of these genes in cells transfected with siRNAs targeting GFP. (C)
Effects of the TGFb receptor inhibitor SB43152 (10 mM for 72 h) on expression of a selected mesenchymal FRA1EMT (TGFBI, AXL) genes in BE cells.
Student’s t-test was used for all comparisons (*p,0.05, **p,0.01, ***p,0.001). Error bars represent S.E.M. for 3 independent experiments.
doi:10.1371/journal.pone.0088950.g006
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EMT-like gene expression signatures have been reported to
correlate with poor prognosis and resistance to targeted therapies
in CRC patients, but the mechanisms governing their genesis are
poorly understood [12–15]. Our findings suggest that FRA1-
regulated transcriptional events play an important role in this
process, with elevated levels of pro-mesenchymal FRA1 targets
associated with adverse outcomes in about half of all stage B and
stage C cancers, while high levels of FRA1 gene (FOSL1)
expression in these mesenchymal-type identifying cancers with
poorest prognosis.
Pathological EMT in CRC strongly linked with tumor budding,
an independent prognostic indicator of higher lymph node
metastasis, vascular and lymphatic invasion, distant metastasis,
local recurrence and poor disease-free survival [9]. While FRA1
expression appears relatively homogenous in tumor cell lines, we
found that it was highly enriched at invasive regions and in
budding cells but not the center of primary tumors. The
mechanism underlying this restricted expression in tumors is
presently unclear, however a similar localization pattern has been
reported for the Wnt pathway transcriptional effector, b-catenin
[40,41]. As b-catenin induces transcription of the FRA1 gene in
CRC cells, FRA1/b-catenin cooperativity may play an important
role in controlling localized transcription of pro-invasive genes in
colorectal tumors, a notion supported by our finding that FRA1
directly binds and regulates several pro-invasive b-catenin targets,
including MMP14, LAMC2, VIM and ZEB1 [11,42–46].
The induction of EMT involves remodeling of multiple cellular
processes, including adhesion, signaling, transcription, and extra-
cellular matrix remodeling. There is growing evidence that tumor
cells often exhibit only some of these changes, for example
expressing a subset of mesenchymal markers while retaining
epithelial features [3]. The ability of tumor cells to transit from an
epithelial to mesenchymal-like state is thus likely to be highly
context-specific, and require cooperativity between multiple
signaling and transcriptional networks. The ability of FRA1 to
bind and regulate genes involved in different EMT-associated
processes suggests that it may play an important role in
coordinated EMT events. Interestingly, in BE CRC cells, FRA1
binding was involved both in maintaining expression of pro-
mesenchymal genes, while repressing an epithelial subset. Several
potential mechanisms may contribute to these opposing effects of
FRA1, including its assembly into distinct FRA1/Jun complexes
within the same cells, its coupling with different signaling
networks, and ability to promote expression of the master EMT
transcriptional factors, ZEB1 and/or SNAI2. Additionally, FRA1
binding may result in localized changes in chromatin dynamics, a
role recently ascribed to AP-1 in regulating the inducibility of
glucorticoid receptor targets [47]. FRA1 may thus contribute to
the generation of permissive chromatin contexts, necessary for
both the reprogramming of CRC cells to a mesenchymal state,
and subsequently to sustain the operation of mesenchymal
programs when tumour cells disseminate. Interestingly, the major
regions of AP-1 binding identified previously near glucocorticoid
Figure 7. FRA1 controls pro-mesenchymal transcriptional responses induced by TGFb in CRC cells. (A) Immunoblot analysis of
endogenous FRA1 expression in BE and SW837 CRC cells. (B) qRT-PCR analysis comparing relative expression levels of a selection of mesenchymal
(AXL, VIM) and epithelial (CDH1, CLDN7) FRA1EMT genes in BE and SW837 CRC cells. (C) Effects of transient FRA1 knockdown on TGFb1-induced (10 ng/
mL 48 h) expression of VIM, CDH1 and CLDN7 in SW837 cells. Student’s t-test was used for all comparisons (*p,0.05). Error bars represent S.E.M. for 3
independent experiments.
doi:10.1371/journal.pone.0088950.g007
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receptor targets and in the present study occurred upstream of
target gene promoters or within introns, implicating a role for
FRA1 in transcriptional control at an enhancer level and/or
downstream of transcription initiation (e.g. elongation).
While stable FRA1 knockdown invoked a MET-like phenotypic
change in BE cells, we have noted that many FRA1-overexpress-
ing CRC cell lines retain epithelial features (ASD, unpublished).
Thus FRA1 expression alone is not sufficient to drive EMT-like
cellular changes, but may do so in cooperation with other
pathways. Indeed, we identified components of several signaling
networks as direct FRA1 targets in BE cells, with the most highly
represented acting in the TGFb pathway. We found that an
underlying function of FRA1 in CRC cells was to positively
regulate TGFb signaling, which it could do via several mecha-
nisms; in the mesenchymal-like BE cell line, its binding modulated
expression of multiple TGFb pathway components, including
maintaining operation of an autocrine TGFb2 loop that promoted
expression of mesenchymal genes. However, in epithelial-like
SW837 CRC cells where autocrine TGFb signaling was not
established, FRA1 was required for TGFb-induced mesenchymal
gene expression responses. Collectively our findings suggest that
FRA1 may play an important role in coupling oncogenic RAS-
ERK signaling with the TGFb pathway to control EMT-like
responses in CRC cells. We suggest that FRA1 may have a similar
function in other cancers where it is overexpressed such as breast,
where FRA1 has recently been shown to play an important role in
regulating EMT events and metastasis [25,48], and in which the
TGFb and RAS-ERK pathways have been reported to cooperate
during EMT induction [19].
From a clinical perspective, our findings are consistent with
recent work showing that induction of EMT is impaired in
microsatellite instable (MSI) colon cancer cells due to the presence
of TGFBR2 mutations [22]. Interestingly, CRC cells harboring
SMAD4 mutations were found to retain the ability to undergo
EMT-like changes in response to TGFb by coupling with the ERK
pathway. We suggest that FRA1 may be a critical ERK pathway
effector regulating EMT-like changes in these cells. Consistent
with this notion, we have found that TGFb-mediated induction of
SNAI2 in SMAD4 mutant SW480 CRC cells is regulated FRA1
(ASD, unpublished).
In summary, the present work reveals an unexpectedly
widespread and direct role for FRA1 in transcriptional control
of clinically relevant programs governing epithelial-mesenchymal
plasticity. We also show that these actions of FRA1 are intricately
linked with its coupling to the TGFb signaling network.
Approaches to inactivate FRA1 and/or pathways through which
its pro-malignant actions are mediated may hence provide an
approach to modulate EMT-MET balances and impede the
spread of CRC and other cancers in which the RAS-ERK
pathway is hyperactive.
Materials and Methods
Cell culture
The BE [33,37] and SW837 CRC cell lines were maintained in
Dulbecco’s modified Eagle’s medium (DMEM) supplemented with
2 mM L-glutamine and 10% fetal bovine serum (FBS). Clonal cell
lines stably expressing shRNAs or wild-type FLAG-FRA1 or a
DNA binding defective (R112V/R123V) mutant were generated
using standard retroviral transduction procedures followed by 2
weeks of puromycin selection. Recombinant human TGFb1 and
the ALK inhibitor SB43152 were from Peprotech (New Jersey,
U.S.A.).
Plasmids and antibodies
Two shRNAmirs targeting FRA1 (shFRA1 A: 59
CCTGGTGCCAAGCATCAACA 39 and shFRA1 B: 59 TGGA-
CAGTATCCCACATCCAAC 39) were designed using the RNAi
Codex database [49] and cloned into the LMP retroviral vector
(Open Biosystems). The LMP vector containing a non-silencing
shRNA (shControl) was a gift from Dr Gretchen Poortinga. The
pBABE-puro-FLAG-FRA1 construct was generated by PCR-
mediated fusion of a FLAG epitope to the N-terminus of FRA1.
The following antibodies were used in this study: anti-FRA1 (R-
20; Santa Cruz Biotechnology), anti-FLAG M2 (Sigma-Aldrich),
anti-14-3-3 (Santa Cruz Biotechnology), anti-vimentin (Cell
Signalling Technology), anti-E-Cadherin (BD Transduction Lab-
oratories), anti-ZO-1 (BD Transduction Laboratories), anti-14-3-3
(BD Transduction Laboratories) and anti-b-catenin (BD Trans-
duction Laboratories).
RNA interference
The following siRNAs used in this study were purchased from
Dharmacon (Melbourne, Victoria, Australia): FOSL1 ON-TAR-
GETplus SMARTpool (L-004341-00), siFRA1 custom (59 CAC-
CAUGAGUGGCAGUCAG 39), GFP Duplex I (P-002048-01),
SMAD3 siGENOME SMARTpool (M-020067-00), LEF1 siGEN-
OME SMARTpool (M-015396-00), WNT5A siGENOME
SMARTpool (M-003939-01), TGFB2 siGENOME SMARTpool
(M-010544-00). Cells were transfected with siRNAs at a final
concentration of 25 nM using the DharmaFECT 1 reagent
(Dharmacon).
Immunohistochemistry and immunofluorescence
microscopy
Immunohistochemical staining for FRA1 in tumors was
performed using a rabbit polyclonal antibody (Santa Cruz sc-
605, 1:2000 dilution) and visualised using horseradish peroxidase
conjugated secondary antibody and DAB substrate (Vector
Laboratories). FRA1 expression was intensity was scored 0, 1 or
2, with 0 representing no detectable staining and 2 representing
the strongest staining observed in the sample set. A sample of
human squamous cervix epithelium was used as a positive control.
IHC for epithelial cytokeratins was performed using an AE1/AE3
antibody mix (Chemicon) at a 1:200 dilution and was visualised
with horseradish peroxidase conjugated secondary antibody and
DAB substrate (Vector Laboratories). Tumor budding was defined
as the mean number of clusters of tumor cells (containing at least 4
cells each) adjacent to the tumor front and counted in two
consecutive 406power microscopy fields, within the region of the
slide displaying most budding. FRA1 expression and the extent of
tumor budding were both scored in a blinded fashion by two
medical pathologists. For immunofluorescence analysis, cells were
cultured on glass coverslips for 24 h prior to fixation (4%
paraformaldehyde in PBS), permeabilization (0.2% Triton-X100
in PBS) and blocking (10% FBS in PBS), each for 20 min at room
temperature. The cells were stained with primary antibodies
(1:200 anti-ZO-1 or 1:75 anti-vimentin; diluted in PBS/0.1%
BSA) followed by secondary antibodies (anti-mouse IgG or anti-
rabbit IgG coupled to Alexa-488 or Alexa-594, Invitrogen), each
for 1 h at room temperature. Nuclei were stained with DAPI
(Invitrogen) prior to mounting the coverlips using Mowiol (10%
Hopval 5–88, 25% glycerol, 0.1M Tris pH 8.5). Images were
taken on an Olympus Fluoview FV1000 confocal microscope.
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Migration, invasion and proliferation assays
Seventy-five thousand cells were seeded in triplicate into 24-well
cell culture inserts (8 mm pore, BD Biosciences) for migration
assays or into BD BioCoat invasion chambers (BD Biosciences) for
invasion assays. As chemoattractant, 10% FBS was added in the
bottom chamber. After 24 hours, cells on the upper filter surface
were removed with a cotton swab, while those on the lower surface
were fixed and stained using the Diff-Quick staining kit (Lab Aids).
Cell migration or invasion was quantified by counting eight
random fields per filter using a light microscope (Olympus BX51).
To assess proliferation, 35000 cells were seeded in quadruplicate
into 24-well plates and assayed for cell density at 4 hour intervals
over 72 hours using the IncuCyteTMFLR live-cell imaging system
(Essen BioScience). The data was analysed using the IncuCyteTM
cell proliferation assay algorithm.
Microarrays, RNA-Seq and RT-qPCR
RNA was purified from cells using the Isolate RNA Mini kit
(Bioline). Microarray analysis using Affymetrix GeneChipH
Human Gene 1.0 ST Arrays was performed on 4 biological
replicates per cell line at the UNSW Ramaciotti Centre for Gene
Expression Analysis. Microarray data was analysed using the R
(http://www.R-project.org), Affy [50] and Limma packages [51].
Robust multi-array average (RMA) normalisation and background
correction was used to remove any non-biological variations in the
data, which was then fitted using a linear model. Contrasts were
used to estimate differential expression and standard errors. Next,
we filtered the data by applying a 2-fold change cut off and
selecting genes with false discovery rate (fdr) adjusted p-values [52]
of less than 0.05. RNA-Seq analysis was performed on 4 biological
replicates per cell line using an Illumina HiSeq 2000 instrument
(Illumina). The 50 bp paired-end reads generated were aligned to
the genome using Bowtie2 [53] and the reads counted using
HTSeq. The differential expression was then calculated utilizing
the DESeq package [54].Heatmaps were generated using R
package gplots. For real-time quantitative PCR (RT-qPCR), RNA
was reverse transcribed using the ThermoScript RT-PCR system
(Invitrogen) for first-strand cDNA synthesis. The cDNA was PCR-
amplified in triplicate using the Fast SYBR green dye on the
StepOnePlus Real-Time PCR system (Applied Biosystems).
Relative expression was determined using BEshControl or
BEsiGFP cells as reference samples, and GAPDH as an internal
control. Sequences of primers used in this study are provided in
Table S8 in File S1.
ChIP and ChIP-Seq
Chromatin immunoprecipitation (ChIP) was performed as
described previously [55]. For each ChIP assay, we incubated
25 ml of anti-FLAG M2 affinity beads (Sigma-Aldrich) overnight
with cross-linked chromatin fragments from 1.56107 BE cells
stably expressing pBABE-FLAG-FRA1 or empty vector (negative
control). High-throughput sequencing of immunoprecipitated
FLAG/StrepII-FRA1 and input chromatin was performed on an
Illumina Genome Analyzer II (Illumina). We used 12.5 ng of
ChIPed DNA to prepare sequencing libraries and sequenced two
flow cell lanes per sample. Selected FRA1 targets were validated
by ChIP followed by qPCR, with relative enrichment levels
calculated after normalising against background enrichment
determined in the negative control. The 36 bp ChIP-Seq reads
were aligned to the human b37/hg19 reference genome using the
Burrows-Wheeler Aligner (BWA) [56] and peaks were called using
Model-based Analysis of ChIP-Seq (MACS) [57]. Input genomic
sequences served as negative control. Statistical analysis of the
resulting bam file and peaks was performed with the R package
(http://www.R-project.org). The Bioconductor [58], Rsamtools
and ChIPpeakAnno packages [59] were used to extract data from
the bam files and to annotate the predicted peaks. Using custom
scripts, the human genome was split into 1 kb bins and the
number of tags in each bin calculated. Predicted peaks within
250 bp of each other were combined and each resulting peak
matched with a bin. The number of tags at each summit was
calculated and a normalised fold change, taking into account total
reads, was calculated for the summit, peak and bin regions. Each
peak was annotated using Ensembl GRCh37 version 61.
Subsequently, motif analysis was performed using the MEME
suite [60] and the data visualised with the Integrative Genomic
Viewer (IGV 2.0) [61]. Comparison of ChIP-Seq reads near
FRA1EMT genes to a known AP-1 motif (MA0099.1, Jaspar core
database) was performed using FIMO (MEME suite), with a p-
value threshold less than 0.0001. Further data analysis was
performed using the Galaxy platform [62]. The pie chart
illustrating the location of ChIP-Seq reads relative to the
transcription start site (TSS) of FRA1EMT was generated using
SoleSearch [63]. Gene cluster analysis of genes identified by
microarray and ChIP-Seq was performed using GeneGo. EMT-
related genes identified by GeneGo in both datasets were termed
FRA1EMT genes.
Analysis of gene expression in human tumors
Previously published gene expression data were retrieved for
primary colorectal cancers from 91 stage B and 94 stage C patients
from the Royal Melbourne Hospital, Western Hospital, and Peter
MacCallum Cancer Center in Australia, and the H. Lee Moffitt
Cancer Center in the United States [12]. The median age at
cancer diagnosis was 67 years (range 26–92 years); 98 patients
were male and 87 were female. Follow-up and adjuvant treatment
details were available from Biogrid Australia for Australian
patients and the Moffitt Cancer Center Tumor Registry for U.S.
patients. All samples had been analysed using HG-U133Plus2.0
GeneChip arrays (Affymetrix). Array data were RMA normalized
and expression values log2 transformed. For unsupervised
clustering, expression values for FRA1 silencing associated EMT
genes were mean and sample centered followed by divisive
hierarchical clustering using pair distances calculated as 1 minus
the Spearman r as distance metric. Differences in mean gene
expression values were calculated for the samples within the two
main branches of the resulting dendrogram and assessed for
statistical significance using the t-test with Benjamini and
Hochberg multiple-testing correction. Relative upregulation or
downregulation of gene expression between these two groups was
assessed for consistency with upregulation or downregulation
observed between FRA1 silencing and control cells using Pearson’s
x2 test. All data processing and analysis were conducted using the
statistical software package R and associated Bioconductor
packages. Data processing and analysis were conducted using
the statistical software package R. Differences between groups
were assessed using the x2 test for categorical variables and the
Wilcoxon rank-sum test for continuous variables. For the outcome
analysis, recurrence-free survival was defined as the time of
surgery to the first confirmed relapse. Kaplan-Meier survival
curves were generated using the PrognoScan algorithm [64].
Censoring was done when a patient died or was alive without
recurrence at last contact. Cox proportional-hazards models were
used to estimate survival distributions and hazard ratios, and were
adjusted for patient characteristics as indicted. All statistical
analyses were 2-sided and considered significant if P,0.05.
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Supporting Information
File S1 Tables S1–S8. Table S1. Relative changes in
expression of FRA1 bound EMT-related genes upon FRA1
knockdown in BE CRC cells. Data represent means from 3
independent RNA-Seq experiments. Table S2. ChIP-Seq reads
identified near FRA1EMT genes. Table S3. AP-1 consensus motifs
identified in FRA1EMT genes. Table S4. Mean gene expression
levels (log2) for the two main groups resulting from unsupervised
clustering of stage B and C colorectal cancers using FRA1EMT
genes. Table S5. Clinicopathological and molecular associations
for FOSL1 expression levels in stage B and C CRC patients. Table
S6. Clinicopathological and molecular associations for FRA1EMT
signature in stage B and C CRC patients. Table S7. Univariate
and multivariate Cox proportional-hazards analysis of survival for
stage B and C colorectal cancer patients according to FOSL1
expression and the concordant FRA1EMT gene expression
patterns. Table S8. List of qRT-PCR and ChIP primers used in
this study.
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